FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980147809> ?p ?o ?g. }

• W2980147809 abstract "Abstract Background Necitumumab (NEC) in combination with gemcitabine+cisplatin (GC) demonstrated significant improvement in overall survival (OS) compared to GC in advanced SqCLC patients (pts) in Global Ph3 study JFCC. In Study JFCM Ph2 part, NEC in combination with GC improved OS compared to GC in SqCLC pts in Japan. Population PK/PD analysis including Study JFCM was conducted to determine the adequacy of the dose in pts in Japan based on NEC PK, and relationship between exposure and efficacy and safety. Methods Two studies, one of which Study JFCM, were added into the analysis previously performed with five Ph 1, 2, and 3 studies. The effect of Japan/non-Japan origin on NEC PK was assessed. Simulations were performed to compare predicted NEC serum concentrations after flat 800 mg and body weight based dosing. The relationship between exposure and OS in Studies JFCC and JFCM Ph2 part was explored. The relationship between exposure and safety measurements (hypomagnesemia, rash and thromboembolic events) in Studies JFCC and JFCM Ph2 part was explored. Results Population PK analysis included blood samples collected from 967 pts (including 114 pts in Japan) treated with NEC. PK parameters were similar between Japanese and non-Japanese pts. NEC PK is dependent on body weight; however, simulations indicated weight-based dosing would not significantly decrease PK variability. Exposure-response analysis included 1195 pts, including 181 pts in Japan. Exposure-efficacy analysis suggested that pts with higher NEC concentration had longer OS, however, majority of pts in both studies had steady state exposure greater than EC80. No correlation was observed between NEC serum exposure and severity of hypomagnesemia or rash. No correlation was observed between NEC serum exposure and risk of treatment emergent thromboembolic events. Conclusion Population PK/PD analysis supports the administration of 800 mg NEC on Day 1 and 8 of a 21-day cycle as an appropriate dose in SqCLC pts in Japan." @default.
• W2980147809 created "2019-10-18" @default.
• W2980147809 creator A5024261346 @default.
• W2980147809 creator A5031434066 @default.
• W2980147809 creator A5050855780 @default.
• W2980147809 creator A5052807157 @default.
• W2980147809 creator A5055671933 @default.
• W2980147809 creator A5056353703 @default.
• W2980147809 creator A5063822136 @default.
• W2980147809 date "2019-10-01" @default.
• W2980147809 modified "2023-09-24" @default.
• W2980147809 title "Population PK/PD Analysis of Necitumumab: Dose justification for Squamous Cell Lung Cancer (SqCLC) Patients in Japan" @default.
• W2980147809 doi "https://doi.org/10.1093/annonc/mdz338.082" @default.
• W2980147809 hasPublicationYear "2019" @default.
• W2980147809 type Work @default.
• W2980147809 sameAs 2980147809 @default.
• W2980147809 citedByCount "0" @default.
• W2980147809 crossrefType "journal-article" @default.
• W2980147809 hasAuthorship W2980147809A5024261346 @default.
• W2980147809 hasAuthorship W2980147809A5031434066 @default.
• W2980147809 hasAuthorship W2980147809A5050855780 @default.
• W2980147809 hasAuthorship W2980147809A5052807157 @default.
• W2980147809 hasAuthorship W2980147809A5055671933 @default.
• W2980147809 hasAuthorship W2980147809A5056353703 @default.
• W2980147809 hasAuthorship W2980147809A5063822136 @default.
• W2980147809 hasConcept C126322002 @default.
• W2980147809 hasConcept C2777288759 @default.
• W2980147809 hasConcept C2778570526 @default.
• W2980147809 hasConcept C2908647359 @default.
• W2980147809 hasConcept C71924100 @default.
• W2980147809 hasConcept C90924648 @default.
• W2980147809 hasConcept C99454951 @default.
• W2980147809 hasConceptScore W2980147809C126322002 @default.
• W2980147809 hasConceptScore W2980147809C2777288759 @default.
• W2980147809 hasConceptScore W2980147809C2778570526 @default.
• W2980147809 hasConceptScore W2980147809C2908647359 @default.
• W2980147809 hasConceptScore W2980147809C71924100 @default.
• W2980147809 hasConceptScore W2980147809C90924648 @default.
• W2980147809 hasConceptScore W2980147809C99454951 @default.
• W2980147809 hasLocation W29801478091 @default.
• W2980147809 hasOpenAccess W2980147809 @default.
• W2980147809 hasPrimaryLocation W29801478091 @default.
• W2980147809 hasRelatedWork W1976458541 @default.
• W2980147809 hasRelatedWork W2069619048 @default.
• W2980147809 hasRelatedWork W2144446166 @default.
• W2980147809 hasRelatedWork W2259886307 @default.
• W2980147809 hasRelatedWork W2319644459 @default.
• W2980147809 hasRelatedWork W2323783599 @default.
• W2980147809 hasRelatedWork W2342481353 @default.
• W2980147809 hasRelatedWork W2508585526 @default.
• W2980147809 hasRelatedWork W2560499829 @default.
• W2980147809 hasRelatedWork W2560857104 @default.
• W2980147809 hasRelatedWork W2601347307 @default.
• W2980147809 hasRelatedWork W2630105953 @default.
• W2980147809 hasRelatedWork W2794235253 @default.
• W2980147809 hasRelatedWork W2943986459 @default.
• W2980147809 hasRelatedWork W2954519260 @default.
• W2980147809 hasRelatedWork W2979673179 @default.
• W2980147809 hasRelatedWork W2999761180 @default.
• W2980147809 hasRelatedWork W3081588620 @default.
• W2980147809 hasRelatedWork W3082838910 @default.
• W2980147809 hasRelatedWork W3082936327 @default.
• W2980147809 isParatext "false" @default.
• W2980147809 isRetracted "false" @default.
• W2980147809 magId "2980147809" @default.
• W2980147809 workType "article" @default.